APA

Beg M. S., Huang X., Silvers M. A., Gerber D. E., Bolluyt J., Sarode V., Fattah F., Deberardinis R. J., Merritt M. E., Xie X., Leff R., Laheru D. & Boothman D. A. (20170905). Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. : Journal of surgical oncology.

Chicago

Beg Muhammad Shaalan, Huang Xiumei, Silvers Molly A, Gerber David E, Bolluyt Joyce, Sarode Venetia, Fattah Farjana, Deberardinis Ralph J, Merritt Matthew E, Xie Xian-Jin, Leff Richard, Laheru Daniel and Boothman David A. 20170905. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. : Journal of surgical oncology.

Harvard

Beg M. S., Huang X., Silvers M. A., Gerber D. E., Bolluyt J., Sarode V., Fattah F., Deberardinis R. J., Merritt M. E., Xie X., Leff R., Laheru D. and Boothman D. A. (20170905). Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. : Journal of surgical oncology.

MLA

Beg Muhammad Shaalan, Huang Xiumei, Silvers Molly A, Gerber David E, Bolluyt Joyce, Sarode Venetia, Fattah Farjana, Deberardinis Ralph J, Merritt Matthew E, Xie Xian-Jin, Leff Richard, Laheru Daniel and Boothman David A. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. : Journal of surgical oncology. 20170905.